| Entry |
|
|---|
| Name |
Verapamil (USAN/INN)
|
|---|
| Formula |
C27H38N2O4
|
|---|
| Exact mass |
454.2832
|
|---|
| Mol weight |
454.6016
|
|---|
| Structure |
     |
|---|
| Activity |
Vasodilator [coronary]
|
|---|
| Remark |
|
|---|
| Comment |
Class IV antiarrhythmic agent
|
|---|
| Target |
calcium channel L type blocker [HSA: 775 776 778 779] [KO: K04850 K04851 K04853 K04857]; potassium inwardly-rectifying channel (KCNJ6) blocker [HSA: 3763] [KO: K05000]; voltage-gated potassium channel (KCNA10) blocker [HSA: 3744] [KO: K04881]; voltage-gated potassium channel (KCNA3) blocker [HSA: 3738] [KO: K04876]; voltage-gated potassium channel (KCNA7) blocker [HSA: 3743] [KO: K04880]; voltage-gated potassium channel (KCNC2) blocker [HSA: 3747] [KO: K04888] |
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP1A2 [HSA: 1544], CYP3A5 [HSA: 1577], CYP3A7 [HSA: 1551]
|
|---|
| Interaction |
CYP inhibition: CYP1A2 [HSA: 1544], CYP2D6 [HSA: 1565], CYP3A [KO: K07424]
Transporter inhibition: ABCB1 [HSA: 5243], ABCB4 [HSA: 5244], SLC22A3 [HSA: 6581]
 |
|---|
| Pathway map |
|
|---|
| Structure map |
| Calcium channel blocking drugs | | Antiarrhythmic drugs | | Antimigraines |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C08 CALCIUM CHANNEL BLOCKERS
C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
C08DA Phenylalkylamine derivatives
C08DA01 Verapamil
D02356 Verapamil (USAN/INN)
USP drug classification [BR:br08302]
Cardiovascular Agents
Calcium Channel Blocking Agents
Nondihydropyridines
Verapamil
D02356 Verapamil (USAN/INN)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated cation channels
Ca2+ channel, CACN alpha-1, CaVx.x
calcium channel L type [HSA:775 776 778 779] [KO:K04850 K04851 K04853 K04857]
Verapamil [ATC:C08DA01]
D02356 Verapamil (USAN/INN)
K+ channel, KCNA, Kv1.x (Shaker)
voltage-gated potassium channel (KCNA3) [HSA:3738] [KO:K04876]
Verapamil [ATC:C08DA01]
D02356 Verapamil (USAN/INN)
voltage-gated potassium channel (KCNA7) [HSA:3743] [KO:K04880]
Verapamil [ATC:C08DA01]
D02356 Verapamil (USAN/INN)
voltage-gated potassium channel (KCNA10) [HSA:3744] [KO:K04881]
Verapamil [ATC:C08DA01]
D02356 Verapamil (USAN/INN)
K+ channel, KCNC, Kv3.x (Shaw)
voltage-gated potassium channel (KCNC2) [HSA:3747] [KO:K04888]
Verapamil [ATC:C08DA01]
D02356 Verapamil (USAN/INN)
Related to voltage-gated cation channels
Inward rectifier channel (Kir)
potassium inwardly-rectifying channel (KCNJ6) [HSA:3763] [KO:K05000]
Verapamil [ATC:C08DA01]
D02356 Verapamil (USAN/INN)
 |
|---|
| Other DBs |
CAS: 52-53-9 PubChem: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 33
1 C1d C 21.2293 -18.3108
2 C8y C 20.0265 -19.0115
3 C1b C 22.4436 -19.0056
4 C1c C 21.2001 -16.9563
5 C8x C 18.8122 -18.3108
6 C8x C 20.0265 -20.4125
7 C1b C 23.6580 -18.3049
8 C1a C 22.4146 -16.2441
9 C1a C 19.9916 -16.2557
10 C8y C 17.5979 -19.0115
11 C8x C 18.8122 -21.1190
12 C1b C 24.8665 -18.9939
13 C8y C 17.5979 -20.4125
14 O2a O 16.3778 -18.3108
15 N1c N 26.0808 -18.2991
16 O2a O 16.3778 -21.1190
17 C1a C 15.1634 -19.0115
18 C1b C 27.2951 -18.9881
19 C1a C 26.0808 -16.8455
20 C1a C 15.1634 -20.4183
21 C1b C 28.5094 -18.2932
22 C8y C 29.7120 -18.9822
23 C8x C 30.9265 -18.2815
24 C8x C 29.6480 -20.3775
25 C8y C 32.1351 -18.9764
26 C8x C 30.9322 -21.0781
27 C8y C 32.1409 -20.3716
28 O2a O 33.3493 -18.2700
29 O2a O 33.3610 -21.0722
30 C1a C 34.5695 -18.9647
31 C1a C 34.5752 -20.3658
32 C3b C 21.2293 -19.7108
33 N3a N 21.2293 -21.1108
BOND 34
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 2
5 2 6 1
6 3 7 1
7 4 8 1
8 4 9 1
9 5 10 1
10 6 11 2
11 7 12 1
12 10 13 2
13 10 14 1
14 12 15 1
15 13 16 1
16 14 17 1
17 15 18 1
18 15 19 1
19 16 20 1
20 18 21 1
21 21 22 1
22 22 23 1
23 22 24 2
24 23 25 2
25 24 26 1
26 25 27 1
27 25 28 1
28 27 29 1
29 28 30 1
30 29 31 1
31 11 13 1
32 26 27 2
33 1 32 1
34 32 33 3
|
|---|
